Section: 
School of pharmacotherapy
School of pharmacotherapyTherapeutic effect of the preparation Aqua Maris® Ectoin in patients with allergic intermittent rhinitis
M. A. Mokronosova (1), T. M. Zheltikova (1), A. S. Aref’eva (1), G. D. Tarasova (2)
(1) Federal State Budgetary Scientific Institution Scientific Research Institute of Vaccines and Serums named after I. I. Mechnikov, Moscow, Russia
(2) Federal State Budgetary Institution Clinical Research Centre for Otorhinolaryngology to the Federal Medico-Biological Agency of the Russian Federation, Moscow, Russia
UDK: 616.211-002-056.3
DOI: https://doi.org/10.18692/1810-4800-2017-2-142-148
ABSTRACT
The objective of the work: to assess therapeutic efficacy on the preparation AquaMaris® Ectoin as a “barrier solution” for patients with AIR.
Patients and methods. The examination was performed at the period of April, 17 to May 24, 2015 in Moscow region. 36 patients at the age of 20 to 45 years with AIR were observed. According to the general diagnostic standards the examination included: medical history data, survey, skin test with the basic set of inhalation allergens, defining the specific IgE-antibodies to pollen antigens in the serum, cytological analysis of the nasal secretion, otorhinolaryngological examination with the topical syndromes record.
The spray AquaMaris® Ectoin used in the work is a natural product that contains a combination of ectoin and isotonic solution of sea salt. The patients were prescribed the preparation Aqua Maris® Ectoin according to the following treatment regimen: 1–2 spray into each nostril 3–4 times per day. When required the preparation was allowed to use as frequently as necessary.
Results. All the patients were divided into 3 groups:
- Group 1 – the patients in which the application of the preparation Aqua Maris® Ectoin resulted in reduction of the syndromes (20 of 34 patients; 59%);
- Group 2 – the patients in which the condition became worse (6 of 34 patients; 18%);
- Group 3 – the patients in which the AIR symptoms severity did not change (8 of 34 patients; 23%).
Therefore, the number of patients in which the application of the preparation Aqua Maris® Ectoin resulted in reduction of the syndromes exceeded the number of patients where the AIR symptoms severity did not change or the condition became worse, by 2.6 and 3.3 times.
The highest number of patients noted the following symptoms of deterioration of the condition: conjunctiva and lids inflammation, tears, nasal itching, post-nasal drip, impaired olfaction against the background of the low concentration of eosinophils in the nasal secretion.
Conclusion. Therefore, the application of the monotherapy with the preparation Aqua Maris® Ectoin at the early stage of development of allergic seasonal inflammation of the upper respiratory tract provides significant decrease in the allergic load on the nasal mucosa of the sensitized organism. In view of this fact, the inclusion of the preparation Aqua Maris® Ectoin into the standard of allergic rhinitis treatment as a “barrier solution” is deemed important.
Publication date:
06.05.2017
Keywords:
allergic rhinitis, pollen, barrier therapy. For citation:
Mokronosova M. A., Zheltikova T. M., Aref’eva A. S., Tarasova G. D. Therapeutic effect of the preparation Aqua Maris® Ectoin in patients with allergic intermittent rhinitis. Rossiiskaya otorinolaringologiya. 2017;2:142–148. https://doi.org/10.18692/1810-4800-2017-2-142-148